NASDAQ:ELYM
Eliem Therapeutics, Inc.
- Stock
Last Close
8.18
17/05 20:00
Market Cap
79.27M
Beta: -
Volume Today
318.37K
Avg: 17.85K
PE Ratio
−1.98
PFCF: −2.60
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 2.20M - | -1.05M 147.65% | -3.25M 209.88% | |||
average payables | 866.50K - | 1.25M 43.68% | 1.08M 13.49% | 408K 62.12% | ||
average receivables | 3.26M - | 6.51M 99.52% | 4.26M 34.57% | |||
book value per share | 3.01 - | 1.85 38.65% | 13.64 637.37% | 4.89 64.13% | 3.99 18.50% | |
capex per share | ||||||
capex to depreciation | ||||||
capex to operating cash flow | ||||||
capex to revenue | ||||||
cash per share | 3.10 - | 1.76 43.41% | 11.13 533.64% | 4.70 57.81% | 3.96 15.73% | |
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.00 - | 0.00 11.15% | ||||
debt to equity | 0.00 - | 0.00 13.02% | ||||
dividend yield | ||||||
earnings yield | -0.03 - | -0.06 77.72% | -0.37 496.42% | -0.47 26.86% | -0.48 2.62% | |
enterprise value | 87.48M - | 164.93M 88.53% | 81.32M 50.69% | 53.46M 34.26% | -19.90M 137.22% | |
enterprise value over ebitda | -45.30 - | -57.55 27.03% | -2.29 96.02% | -1.22 46.54% | 0.49 140.34% | |
ev to operating cash flow | -17.47 - | -11.70 33.03% | -2.25 80.73% | -1.43 36.55% | 0.97 167.52% | |
ev to sales | ||||||
free cash flow per share | -0.73 - | -1.21 65.04% | -2.94 143.37% | -1.42 51.73% | -0.76 46.26% | |
free cash flow yield | -0.05 - | -0.08 65.04% | -0.28 269.94% | -0.39 37.58% | -0.28 26.95% | |
graham net net | 2.99 - | 1.49 50.02% | 11.22 650.77% | 4.52 59.71% | 3.91 13.54% | |
graham number | 6.14 - | 6.41 4.41% | 34.47 437.88% | 13.77 60.04% | 10.80 21.56% | |
income quality | 0.76 - | 0.68 10.83% | 0.76 11.38% | 0.83 8.72% | 0.59 28.98% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -28.33 - | |||||
interest debt per share | 0.08 - | 0.01 83.59% | ||||
inventory turnover | ||||||
invested capital | 0.00 - | 0.00 13.02% | ||||
market cap | 108.71M - | 185.42M 70.57% | 128.25M 30.84% | 96.56M 24.70% | 72.87M 24.54% | |
net current asset value | 20.50M - | 18.93M 7.63% | 142.21M 651.06% | 128.12M 9.91% | 107.39M 16.18% | |
net debt to ebitda | 10.99 - | 7.15 34.96% | 1.32 81.51% | 0.99 25.28% | 2.30 133.24% | |
net income per share | -0.56 - | -0.99 77.72% | -3.87 292.36% | -1.72 55.49% | -1.30 24.50% | |
operating cash flow per share | -0.73 - | -1.21 65.04% | -2.94 143.37% | -1.42 51.73% | -0.76 46.26% | |
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.18 - | -0.47 163.31% | -0.27 41.35% | -0.34 22.59% | -0.32 5.38% | |
revenue per share | ||||||
roe | -0.18 - | -0.53 189.70% | -0.28 46.79% | -0.35 24.08% | -0.33 7.37% | |
roic | -0.21 - | -0.54 157.89% | -0.21 60.51% | -0.35 63.54% | -0.37 6.92% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | 3.01 - | 1.85 38.65% | 13.64 637.37% | 4.89 64.13% | 3.99 18.50% | |
stock based compensation to revenue | ||||||
tangible asset value | 20.61M - | 21.57M 4.64% | 167.20M 675.24% | 128.72M 23.02% | 107.60M 16.41% | |
tangible book value per share | 3.01 - | 1.85 38.65% | 13.64 637.37% | 4.89 64.13% | 3.99 18.50% | |
working capital | 20.50M - | 18.93M 7.63% | 142.22M 651.10% | 128.30M 9.79% | 107.42M 16.27% |
All numbers in USD (except ratios and percentages)